The archive · Health & Care · Product decision · 2018–2025
Abridge bets ambient AI on doctor-patient talks; $300M Series E at $5.3B
A cardiologist's scribe app becomes care intelligence: 150+ health systems, $5.3B valuation.
Abridge
What the business is
Abridge sells a generative AI platform that ambiently listens to clinician-patient conversations and drafts structured, specialty-specific, billing-ready notes for the EHR.
Starting capital：About $27M raised by mid-2022, then $250M Series D (Feb 2025) and $300M Series E (Jun 2025)
How it started
Rao, a UPMC cardiologist and former UPMC Enterprises executive, co-founded Abridge in 2018 after realizing he spent more time on notes than with patients. The company first built a patient-facing app that recorded and summarized medical conversations, then launched an enterprise ambient documentation product in 2022 backed by a $12.5M Series A-1 led by Wittington Ventures.
What happened
Abridge scaled from about 100 US health systems at its February 2025 Series D (co-led by Elad Gil and IVP) to 150+ by June. Its Contextual Reasoning Engine drafts billable notes at the point of care and pushes into revenue cycle management; the company was named Best in KLAS for Ambient AI and invested in by CVS Health Ventures and NVIDIA.
How it ended up
In June 2025 Abridge closed a $300M Series E led by Andreessen Horowitz with Khosla Ventures, at a reported $5.3B valuation. It said it would support clinicians across more than 50 million medical conversations that year, in 55 specialties and 28 languages, and claimed up to 60-70% burnout reduction with over 90% of clinicians continuing to use it.
Background
Abridge began with a personal frustration: founder Dr. Shiv Rao, a UPMC cardiologist, was spending more time writing notes than seeing patients. He co-founded Abridge in 2018, first building a consumer app that let patients record and understand their medical conversations, before launching an enterprise ambient-documentation product in 2022.
The core bet was that the clinical conversation itself is the most valuable data in healthcare. Instead of asking clinicians to type into an EHR, Abridge listens in real time and generates specialty-specific, billing-compliant notes, with its Contextual Reasoning Engine encoding payer rules and risk-adjustment models so documentation is correct at the point of care rather than fixed weeks later.
The market accepted the thesis quickly: by February 2025 Abridge had passed 100 US health system deployments and raised a $250M Series D co-led by Elad Gil and IVP; by June 2025 it counted more than 150 enterprise health systems, expected to support over 50 million medical conversations that year across 55 specialties and 28 languages, and claimed 60-70% burnout reduction for adopting clinicians.
The $300M Series E, led by Andreessen Horowitz with Khosla Ventures, valued the company at about $5.3 billion. The funding was aimed at moving from documentation into revenue cycle management — turning every conversation into the code- and evidence-rich substrate the whole billing system runs on.
What has to be true
- Rao combined first-hand clinical credibility with the same painful workflow his product removes, which made health systems trust and pilot the tool.
- Ambient documentation attacks an acute, measurable problem — clinician burnout and billions in administrative cost — so ROI was demonstrable early.
- Building billing and coding intelligence directly into the model made the scribe sticky: it stopped being a nice-to-have and became part of how claims get paid.
- Landed enterprise logos (UPMC, Inova, and 150+ systems) plus strategic backers like CVS Health Ventures and NVIDIA compounded credibility.
- Expanding from notes to the revenue cycle widened the addressable market from documentation to the $1.5T US administrative-spend problem.
What can be applied
Start inside a painful workflow with a founder who lived it; a single documented pain grew into the revenue-cycle layer of an entire industry.
Aftermath
As of June 2025 Abridge was actively scaling: 150+ US health systems, expansion of its platform into revenue cycle management, and hiring across engineering and clinical teams. It remained private with no exit announced; its reported $5.3B valuation made it one of the most valuable healthcare AI startups, with competitors including Ambience Healthcare and Suki.
Sources
- Abridge Secures $300M Series E Led by a16z to Pioneer a New Paradigm of Care Intelligence
- Gen AI company Abridge raises $300M, targets revenue cycle
- Abridge Announces $250M Series D Investment and New Contextual Reasoning Engine
- Poised to revolutionize the care delivery experience through AI, Abridge secures $12.5M in funding
spotted an error? The archive wants to know.
Your turn
You just read one. Describe what you are building, and see who is betting on the same thing.
Free account · 3 free questions · no card